PHBI (Pharmagreen Biotech) Forward Dividend Yield %: 0.00% (As of Jul. 01, 2026)


What is Pharmagreen Biotech Forward Dividend Yield %?

Pharmagreen Biotech PHBI Forward Dividend Yield % is 0.00% as of Jul. 01, 2026.

As of today (2026-07-01), the Forward Annual Dividend Yield of Pharmagreen Biotech is 0.00%.

As of today (2026-07-01), the Trailing Annual Dividend Yield of Pharmagreen Biotech is 0.00%.

PHBI's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.08
* Ranked among companies with meaningful Forward Dividend Yield % only.

Pharmagreen Biotech's Dividends per Share for the three months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Pharmagreen Biotech  (OTCPK:PHBI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Pharmagreen Biotech Forward Dividend Yield % Related Terms

PHBI vs DVLP, CSTF, BLMS: Forward Dividend Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech Forward Dividend Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's Forward Dividend Yield % falls into.


Pharmagreen Biotech Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Pharmagreen Biotech (PHBI) has a Forward Dividend Yield % of 0.00% as of Jul. 01, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Pharmagreen Biotech and its competitors.
Is Pharmagreen Biotech's Forward Dividend Yield % too high?
Pharmagreen Biotech's current Forward Dividend Yield % is 0.00%.
How does Pharmagreen Biotech's Forward Dividend Yield % compare to DVLP and CSTF?
Pharmagreen Biotech's Forward Dividend Yield % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median Forward Dividend Yield % is 2.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.08, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Pharmagreen Biotech and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmagreen Biotech's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmagreen Biotech stock overvalued right now?
Pharmagreen Biotech (PHBI) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Pharmagreen Biotech (PHBI), the current Forward Dividend Yield % is 0.00% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmagreen Biotech Business Description

Address 112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.